Chester Kao

<i>LRP1B</i> mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types

Landon C. Brown, Matthew D. Tucker, Ramy Sedhom et al. · Journal for ImmunoTherapy of Cancer · 2021 · 109 citations · Full text

High Expression of miR-532-5p, a Tumor Suppressor, Leads to Better Prognosis in Ovarian Cancer Both <i>In Vivo</i> and <i>In Vitro</i>

Fan Wang, Jeremy Chang, Chester Kao et al. · Molecular Cancer Therapeutics · 2016 · 56 citations · Full text

Epigenetic Regulation, Medicine, High Expression +14

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma

Matthew D. Tucker, Landon C. Brown, Yu‐Wei Chen et al. · Biomarker Research · 2021 · 41 citations · Full text

Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors

Chester Kao, Eric R. Powers, Yuan Wu et al. · Clinical Lung Cancer · 2021 · 30 citations · Full text

Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma

Stephanie Alden, Mir Lim, Chester Kao et al. · Cancer Research Communications · 2023 · 29 citations · Full text